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Abstract
Background: Acute diarrhoea is a common cause of illness and death among children in low- to middle-income
settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children
focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended
except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a
dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk
associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics
for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and
morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.
Methods: ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2–23 months presenting with
acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled
children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin
10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause
mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment.
Discussion: Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may
offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or
other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or
improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of
antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor
antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of
azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present
World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these
results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding
inappropriate use of antibiotics and reaffirming the current guidelines.
Trial registration: Clinicaltrials.gov, NCT03130114. Registered on April 26 2017.
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Background
Acute diarrhoea continues to be one of the most com-
mon illnesses in infants and young children, especially in
low-income settings. Approximately half a million chil-
dren continue to die annually as a result of acute diar-
rhoeal episodes [1], mostly in sub-Saharan Africa or
southeast Asia. The current World Health Organization
(WHO) recommended management guidelines for acute
diarrhoea (rehydration, supplemental zinc, feeding ad-
vice and appropriate follow-up) [2] have contributed to
significant reductions in diarrhoea-associated mortality
[3]. These guidelines do not suggest a role for antibiotics
except in case of bloody diarrhoea (as a proxy for shi-
gella or other invasive bacterial infections) or suspected
cholera.
Data from the large Global Enteric Multicentre Study
(GEMS) [4] show that at least one putative pathogen can
be identified in over 80% of children presenting with
moderate–severe diarrhoea. Similar results were also
seen with a more recent molecular re-analysis of stool
samples from children from low-income settings which
identified a putative pathogen in 65% of children [5]. A
bacterial aetiology was identified in a quarter of all stool
samples studied. The recent global burden of disease
study on childhood diarrhoea indicates that, while rota-
virus is the leading cause of diarrhoea-related deaths
(28%) in young children, bacterial species including Shi-
gella spp. (14.5%), non-typhoid Salmonella spp. (8.4%),
Campylobacter spp. (9%) and Escherichia coli (6.5%) also
contribute to a significant number of deaths in this age
group [1]. These studies suggest a significant role for
bacterial pathogens in diarrhoea-associated deaths [1].
Other studies have also demonstrated that visible blood
in the stool is a poor indicator of a bacterial aetiology in
children with diarrhoea [6, 7], suggesting that the use of
blood in the stool as a proxy for Shigella spp. may be in-
adequate and that the indications for antibiotic use in
young children with acute diarrhoea could be expanded.
Taken together, these studies suggest that current
treatment guidelines may be missing the opportunity to
appropriately provide antibiotics to a highly selected
group of young children who, because of aetiology, dis-
ease severity and/or undernutrition, are at a particularly
high risk of diarrhoea-associated mortality [1, 8, 9].
Azithromycin, a macrolide with a broad spectrum of
antibacterial activity and immunomodulatory properties,
has been administered to children in the context of mass
drug administration programmes largely for trachoma
prevention [10]. Observations of mortality sparing re-
lated to azithromycin administration in these trachoma
interventions prompted several large community trials of
azithromycin administered via mass drug administration
which have shown significant mortality reductions in
children in low-resource settings [11–13].
Given these findings, we are conducting a randomised,
placebo-controlled trial, the Antibiotics for Childhood
Diarrhoea (ABCD) trial, to determine if the addition of
an antibiotic (azithromycin) to the standard manage-
ment for acute non-bloody watery diarrhoea in a subset
of children 2–23 months of age who are dehydrated or
undernourished could reduce the mortality and improve
growth in settings where such deaths commonly occur.
Methods
Aim
The main aim of the ABCD trial is to compare rates of
all-cause mortality in the 180 days following enrolment
for an episode of acute non-bloody diarrhoea among
high-risk children (dehydrated and/or undernourished)
aged 2 to 23 months, living in low-resource settings,
who are randomised to receive a 3-day course of azithro-
mycin or placebo, in addition to the WHO recom-
mended management of acute watery diarrhoea. A
second main aim is to compare the change in linear
growth 90 days after enrolment between the same
groups.
The secondary aims include a comparison of indicators
of acute malnutrition, hospitalisations and/or death. These
are described in detail under the section ‘Outcomes’.
Given the risk of antimicrobial resistance, we plan to com-
pare resistance profiles in nasopharyngeal (Streptococcus
pneumoniae) and stool (E. coli) isolates from a sample of
children from the placebo and treatment arms. The proto-
col for the main trial is described here.
Study design
The ABCD trial is a double-blind, individual rando-
mised, parallel group superiority trial comparing azithro-
mycin with placebo conducted in 11,500 high-risk
children aged 2–23 months, presenting with non-bloody
diarrhoea in seven countries (Bangladesh, India, Kenya,
Malawi, Mali, Pakistan and Tanzania).
The trial protocol was developed by collaborators at
the WHO, Department of Maternal Newborn, Child and
Adolescent Health (Geneva, Switzerland) together with
teams in Dhaka, Bangladesh (the International Centre
for Diarrhoeal Disease Research), New Delhi, India (the
Centre for Public Health Kinetics), Nairobi, Kenya (the
Kenya Medical Research Institute), Blantyre, Malawi (the
Malawi Liverpool Wellcome Trust), Bamako, Mali (the
Centre pour le Développement des Vaccins), Karachi,
Pakistan (the Aga Khan University), Dar es Salaam,
Tanzania (the Muhimbili University of Health and Allied
Sciences), Boston, MA, US (the Boston Children’s
Hospital and Harvard TH Chan School of Public
Health), the University of Maryland, the University of
Washington Department of Global Health and the
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Centre for the Integrated Health of Women, Adolescents
and Children. The study design is described in Fig. 1.
Study setting and population
The study will be implemented in health facilities in the
seven sub-Saharan and south Asian countries listed
above. The countries were selected based on study site
characteristics as well as the strengths and experience of
the investigator teams in conducting large intervention
trials. Within each country, 2–10 individual health facil-
ities will be the sites of patient enrolment.
Inclusion criteria
1. Children aged 2–23 months, presenting to a
designated health care facility at a participating
study site with:
a. Diarrhoea as per caregiver perception and at
least three loose or watery stools in the previous
24 h
b. Diarrhoea for less than 14 days prior to
screening and with at least one of the following
risk criteria at presentation:
(i) Signs of some or severe dehydration as per
the WHO Pocket Book 2013 [14]
(ii) Moderately wasted as defined by a mid-
upper arm circumference (MUAC) <125 mm
(but ≥115 mm) or a weight-for-length z
score (WLZ) greater than −3 and less than
or equal to −2 after rehydration during a sta-
bilisation period
(iii)Severely stunted (length-for-age z score
(LAZ) less than −3 based on WHO norms)
2. Parent or guardian (caregiver) willing to allow
household visits on day 2 and day 3 and willing to
return to facility on day 90 post-enrolment
3. Parent or guardian (caregiver) provides written
consent for trial participation on behalf of the
child
Exclusion criteria
1. Dysentery (blood in stool reported by caregiver or
observed by health care worker)
2. Clinically suspected Vibrio cholerae infection
3. Previously or currently enrolled in the ABCD study
4. Concurrently enrolled in another interventional
clinical trial
5. Sibling or other child in the household enrolled in
the ABCD study and currently taking study
medication
6. Signs of associated infections (pneumonia, severe
febrile illness, meningitis, mastoiditis or acute ear
infection) requiring antibiotic treatment
7. Documented antibiotic use in the 14 days prior to
screening (not including standard use of
prophylactic antibiotics, i.e. co-trimoxazole use in
HIV-exposed children)
Fig. 1 The Antibiotics for Children with Diarrhoea (ABCD) trial study design. AMR antimicrobial resistance
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8. Documented use of metronidazole within the last
14 days
9. Known allergy or contraindication to azithromycin
antibiotics
10. Severe acute malnutrition defined as weight-for-
length z score less than −3, or MUAC less than
115 mm, or oedema of both feet
11. Living at a distance from the enrolment health
centre that prevents adequate directly observed
therapy on day 2 and day 3
Site-specific recruitment plans were made. Each site
will discuss the protocol and its implementation with
medical staff, community health workers in the area and
community leaders in order to increase awareness of the
trial, as well as to encourage referral of eligible children
to enrolling sites.
Screening and enrolment procedures
After a potentially eligible child has been identified, the
study staff will screen the child for eligibility, based on
the above-mentioned inclusion and exclusion criteria,
using a standardised screening form. If the child presents
with diarrhoea and no signs of dehydration, the child is
enrolled if anthropometric criteria are met.
If the child has signs of “some” or “severe” dehydra-
tion, or if the child requires urgent care, they will be
kept under observation. During this “stabilisation”
period, oral and/or intravenous rehydration will be pro-
vided, and treatment of all urgent conditions will be per-
formed using standard treatment in accordance with the
WHO Pocket Book of Hospital Care for Children, 2013
[14]. Assignment to either study drug (azithromycin or
placebo) will not require alteration to the current stand-
ard of care. Once rehydration of the child is successfully
completed, and urgent care has been provided, the child
is enrolled, if eligible. However, if the child is not stabi-
lised, or requires additional treatment, they will not be
screened further.
Anthropometric measurements will be carried out in
accordance with the methods specified in the WHO
module on measuring a child’s growth [15]. Anthropom-
etry measurements will be taken after rehydration and
stabilisation as required. Weight will be measured using
an electronic scale with a sensitivity of ±10 g by two in-
dependent observers; length will be measured using a
length board to the nearest 0.1 cm. Calibration of the in-
struments to measure length and weight will be done
daily. MUAC will be measured using non-stretchable
tape to the nearest 0.1 cm.
Consent
After confirming eligibility, the accompanying primary
caregiver will provide written informed consent. For
caregivers who are illiterate, documented witnessed ver-
bal consent and a thumbprint will be obtained. During
consent, the purpose of the study, as well as all the study
procedures, will be explained to the caregiver by a mem-
ber of the trial team in the local language.
Consent is taken for the collection and storage of and
use of samples collected. Caregivers were informed that
they could request discontinuation of storage and de-
struction of samples collected from the child. Caregivers
were also informed that they could choose to participate
in the trial but not provide samples.
Randomisation, allocation concealment and blinding
Stratified randomisation (by site) will be carried out in
permuted blocks (block size 4,6,8). A computer-
generated randomisation list will be converted into
unique serial numbers for each enrolled child at each
site. Each individual enrolled child’s supply of study
medicine will be provided to each site in advance, la-
belled with this serial number.
To ensure blinding, the containers and doses for each
of the two groups will be identical. The active and pla-
cebo medications will be similar in all aspects including
the colour, smell and taste. The containers will be iden-
tical. Treatment allocation (once assigned) will remain
blinded to the participant, the site Principal Investigator,
the site study staff and the hospital clinicians during all
data collection phases of the study.
The randomisation code is kept with a third-party
agency. The code will only be broken if the Data Safety
and Monitoring Board (DSMB) requests this information
for a participant (because of a suspected relationship be-
tween a serious adverse event and the study drug) or for
unmasking a study arm (as part of the interim analysis).
Interventions
Children will be randomised to one of two arms. Those
randomised to the treatment arm receive azithromycin
10mg/kg as a single dose on 3 consecutive days, recon-
stituted from a dry powder, and given to the children or-
ally. Children randomised to the placebo arm receive an
inactive placebo identical in appearance, also as a dry
powder, reconstituted similarly, and given for 3 consecu-
tive days.
The first dose of the study medicine is given directly
observed at the health facility by a trained study worker.
On days 2 and 3, a study team member will visit the
home of all enrolled children to provide the subsequent
doses of the study medicine, or to observe the caregiver
giving it.
Both groups will receive standard of care for diar-
rhoeal disease, including rehydration, supplemental zinc,
nutritional counselling, follow-up and guidance on when
to return, as per the WHO guidelines. Children with
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some or severe dehydration will be rehydrated and stabi-
lised prior to completion of screening.
Outcomes
Primary outcomes
1. All-cause mortality in the 180 days following
enrolment between the placebo and treatment arms
2. Change in linear growth measured as change in
length-for-age z score (ΔLAZ) in the 90 days follow-
ing enrolment between the placebo and treatment
arms
Secondary outcomes
1. Change in markers of acute malnutrition between
arms (ΔMUAC and ΔWLZ and Δweight)
2. The proportion of children who are hospitalised in
the 90 days following enrolment
3. The proportion of children who are hospitalised or
have died in the 90 days following enrolment
4. The proportion of children who are hospitalised or
have died in the 10 days following enrolment
5. Cause-specific mortality as determined by verbal
and social autopsy
6. Proportion of strains of E. coli, isolated from stools,
resistant to azithromycin and other antibiotics at
enrolment among the study population
7. Proportion of strains of E. coli, isolated from stools,
and S. pneumoniae, isolated from nasopharyngeal
swabs, resistant to azithromycin and other
antibiotics at day 90 and day 180 in a randomly
selected sub-sample of children enrolled in the
study and their siblings or close household contacts
Trial assessments and follow-up
Children enrolled into the trial will be followed up for
180 days post-enrolment or until the first primary end
point is reached, whichever is earlier. The schedule of
enrolment, intervention and follow-up assessments is
shown in Fig. 2, which follows the SPIRIT guidelines.
At day 45, a telephonic or in-person contact will be
made by a non-medical member of the trial team to ascer-
tain the vital status of the child, any hospital admissions
and to remind the patient of the day 90 appointment.
At day 90, participants will be followed-up in the clinic
to ascertain vital status, hospitalisations, and health of
the enrolled child, as well as their nutritional status
(weight, length and MUAC).
Participant retention will be encouraged by the fre-
quent follow-up during days 1–3, the provision to care-
takers of a study telephone number for questions, and
the follow-up schedule noted in Fig. 2. Caretakers of en-
rolled children provided study staff with their home
address and the closest available telephone number on
which they could be contacted. At day 180, study
personnel will contact study participants by telephone or
in person. They will ascertain the vital status of the en-
rolled child at day 180 and document any hospital ad-
missions since the day 90 visit.
If a child is reported to have died at any time during
the study follow-up period, specially trained study staff
will review the hospital record (if available) and conduct
a standardised verbal and social autopsy interview to as-
certain the date, cause and context of death. The verbal
autopsy effort will include capturing all relevant hos-
pital/facility-based information on a child that dies in a
facility.
Antimicrobial resistance
A subset of 1700 ABCD participants will be enrolled in
an antimicrobial resistance (AMR) detection study in the
trial. This AMR component will study the development
of AMR among E. coli (stool isolates) and S. pneumoniae
(nasopharyngeal isolates) in study participants and their
close household contacts.
A faecal stool sample will be collected from all chil-
dren at enrolment for culture and sensitivity testing
of E. coli.
Children enrolled in the AMR sub-study will also be
asked to provide a stool sample and a nasopharyngeal
swab on day 90 and day 180. In addition, a stool sample
and a nasopharyngeal swab will also be collected from a
sibling or other close household contact of the enrolled
child at day 90 and day 180. The protocols for this AMR
detection study will be described elsewhere.
Diarrhoea aetiology
Each site will undertake an assessment of the potential
viral and bacterial pathogens associated with the diar-
rhoeal episode in a separate study. A total of 7000 stool
specimens will be tested. Identification will be facilitated
by quantitative molecular diagnostic methods.
Recording of serious adverse events
Serious adverse events are defined as any deaths or hos-
pitalisation or any life-threatening event that occur in
the period from enrolment to day 10. Although it is rela-
tively safe for use in young children, azithromycin can
cause adverse events including nausea, abdominal pain
[16] and diarrhoea from its effects on the gut microbiota
[17, 18]. Any adverse events in the ABCD trial are moni-
tored by the Trial Steering Committee (TSC) and
reviewed by the DSMB. These events will be recorded by
the trial staff and confirmed by the study physicians.
Study physicians can, at any time, withdraw a participant
from the trial if a risk to their safety from continuation
in the study is perceived.
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Quality assurance
The following measures provide quality assurance:
1. An extensive initial and subsequent ongoing training
sessions for data collectors in the protocol
procedures with a focus on anthropometry
measurements and dehydration assessment to ensure
the reliability between data collectors is high.
2. Real-time electronic data capture will ensure data
validation, such as range, logical checks and data
integrity.
3. Principal Investigators will receive brief monthly
progress reports from the Data Coordinating Centre
during the entire study period and will participate in
regular telephone conferences with WHO staff. The
monthly progress reports will include the number
children assessed, number of children recruited,
home visits due to be conducted, actual visits
conducted, child hospitalisations, deaths and verbal
and social autopsies [19] conducted.
4. Field supervisors will be responsible for assuring
that the training of the field staff is rigorous and of
high quality. They will schedule the testing and
retraining as required at their individual sites.
Assessment of individual study personnel’s abilities
to use the standardised enrolment criteria and
conduct the anthropometric measurements and
dehydration assessment consistently across the
study population are key responsibilities of the
field supervisor.
5. WHO study coordinators, and others identified by
them, will ensure that at least two structured
monitoring visits are conducted to each site every
year. The monitoring visits will have as their
primary aim quality control and the improvement
of study implementation. The monitors will make
direct observations of all relevant study procedures
and data management activities.
6. The data management team will run a monthly set of
range and consistency checks, resolve inconsistencies
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** D1 D1 D1 D2 D3 D45 D90 D180
ENROLMENT:
Eligibility screen* x
Informed consent X
[List other 
procedures] X
Allocation X
INTERVENTIONS:
Study drug
ASSESSMENTS:
Length
xx
Weight
x x
MUAC
x x
Stool sample# 
collection
x x x
Nasopharyngeal# 
swab collection
x x x
Ascertain 
Hospitalization
x x x
Ascertain Mortality 
xx x x
Fig. 2 Schedule of enrolment, intervention and follow-up assessments for the Antibiotics for Children with Diarrhoea (ABCD) trial
*Screening is expected to be completed on the same single day, except is the child needs treatment for dehydration or urgent care for an illness,
in which case, it can be completed once the child has been stabilized.
#Stool samples and nasopharyngeal isolates are only collected for 15% of participants in the antimicrobial resistance study.
D=day.
MUAC=mid-upper arm circumference
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or queries with the sites and provide data summaries
as the trial progresses. The queries will be resolved
before the next set of monthly checks report.
Compensation
No financial compensation will be provided for partici-
pation in the trial. The presenting diarrhoeal episode
and any serious illnesses will be treated at the time of
presentation.
Data management
An external data management agency will ensure har-
monisation of data collection and data management pro-
cesses across all sites. All sites will collect information
on a core set of variables with standard definitions. A set
of range and consistency checks that must be applied to
these variables will be available.
Each site will be responsible for data entry and initial
cleaning of the data, including running range and
consistency checks, as well as periodic reviews of distri-
butions and identification of outliers. Each study site will
resolve any inconsistencies within its database, in con-
sultation with the field data collection team, and with
field verification if needed. Individual sites will be re-
quired to provide data on the core set of variables into a
REDCap database. The data management team will run
a monthly set of range and consistency checks, resolve
inconsistencies or queries with the sites and provide data
summaries as the trial progresses.
Statistical considerations
Sample size and power
To determine the sample size for the ABCD trial, we es-
timated that the 180-day mortality in the control group
would be 2.7%. The estimated overall mortality in the
control group was based on the earlier GEMS trial [4] as
well as the assumed proportions of children with various
risk factors in the sample and respective sub-group-
specific mortality. Assuming this baseline mortality, a
relative risk in the intervention group of 0.65 (35% re-
duction in mortality in the intervention group), 90%
power, 95% confidence, assumed loss to follow-up of
10%, and 1:1 ratio in the numbers of participants in the
control and intervention group, the required sample size
would be 5696 per group or 11,392 in total. Since there
is an initial plan to conduct one interim analysis, the
sample size will be inflated by a factor of 1.009 [20]. The
total planned sample size will be 5750 per group and 11,
500 in total. As the study is implemented in seven coun-
tries, each country will on average need to enrol 1645
children (approximately 822 per study group).
The second primary aim is to compare ΔLAZ between
the control and intervention from enrolment to 90 days.
We have estimated that, with the above sample size, we
will have 80% power to detect at least a 0.04 difference
in mean ΔLAZ between study groups using a two-sided
t test to compare the difference in mean change in LAZ
between two groups with α = 0.05 and standard devi-
ation (SD) of 0.7 in both groups. This is comparable to
results observed in GEMS. As the SD of the difference
in ΔLAZ has been shown to vary, this will provide an
adequate sample size to detect a ΔLAZ ranging between
0.04 and 0.06 given varying SDs between 0.5 to 0.7, with
a power of 80–90%.
Statistical analysis
An intention-to- treat (ITT) approach, including all ran-
domised participants, is considered the primary analysis
approach.
For the first primary outcome, i.e. the mortality out-
come, period prevalence of death will be compared be-
tween the randomly assigned treatment groups using
relative risk regression. Mortality (a binary variable) will
be defined as any event of death from time of random-
isation to end of day 180. Participants with a missing
mortality outcome will be assigned ‘alive’. For the pri-
mary ITT analysis, the following model will be used:
E Y jrandomisation armð Þ¼e β0þβ1Xazmð Þ
where xazm is an indicator variable specifying rando-
mised to the azithromycin group (xazm = 1) or not
(xazm = 0). The risk ratio comparing the risk of death in
children randomised to azithromycin versus placebo will
be determined by eβ. The statistical significance of this
comparison will be determined by a Wald test. In a per-
protocol analysis, secondary to the ITT analysis, relative
risk regression will be fit as described above among the
subset of children with documented completion of the
full course of treatment.
For the co-primary outcome, i.e. ΔLAZ, a linear re-
gression model will be used to compare mean ΔLAZ
across the treatment groups in surviving children. ΔLAZ
will be operationalised as the difference in LAZ between
the 90-day follow-up visit and LAZ at baseline. For the
primary ITT analysis, LAZ outcome will only be ana-
lysed for those children with a measured outcome. The
following model will be used:
E Y jrandomisationarmð Þ ¼ β0 þ βXazm
where Y =mean ΔLAZ, and xazm is an indicator variable
of being randomised to the azithromycin group (xazm = 1)
or not (xazm = 0). The mean difference in ΔLAZ in chil-
dren randomised to azithromycin versus placebo will be
determined by (β). The statistical significance of this com-
parison will be determined by independent t test. In a per-
protocol analysis, also secondary to the ITT analysis, a lin-
ear regression model will be fit as described above among
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the subset of children with documented completion of the
full course of treatment.
A secondary analysis will be done as a per-protocol
analysis excluding participants who are not adherent to
the full treatment schedule or having missing outcomes.
Effect modification by site, age, sex, anthropometry
and socioeconomic status will be explored. This is
planned to be exploratory. No testing within any stratum
is envisaged as there is unlikely to be adequate power to
test within a stratum.
Trial governance
The ABCD trial is overseen by the TSC which consists
of the site Principal Investigators and the WHO Trial
Coordinators. The TSC is responsible for overall super-
vision of the trial. A second committee, the Trial Advis-
ory Group (TAG), consists of external experts with
experience in diarrhoeal disease in low-income contexts.
The TAG provides advice to the TSC periodically during
the life of the trial.
An independent DSMB has been established by the
WHO to monitor severe adverse events and to approve
the statistical analysis plan and associated stopping rules
for benefit, futility, or harm determined using O’Brien-
Fleming stopping boundaries. The DSMB includes five
members with expertise in clinical trials, statistics, child
mortality assessment, ethics, and paediatric care in
resource-limited settings. When approximately half of the
person-time is accrued in the study, the DSMB will review
an interim data analysis by arm to determine whether
stopping boundaries have been crossed. The SPIRIT
checklist for present study is provided in Additional file 1.
Discussion
ABCD is a large, multi-site, paediatric trial testing the
potential benefits of azithromycin in reducing mortal-
ity and improving linear growth when targeted to
high-risk children with non-bloody diarrhoea. A re-
cently concluded cluster randomised trial of mass
drug administration of azithromycin has shown a re-
duction in all-cause mortality among children [11–
13]. However, the effect appeared limited to a single
site in this trial. Another large trial of azithromycin
in addition to seasonal malaria chemoprophylaxis [21]
has not documented any benefit on mortality, al-
though a reduction in gastrointestinal infections was
seen. The potential effect of azithromycin on mortal-
ity in children with a high risk of a diarrhoea-related
death has not been studied to date.
Young children who are undernourished or have dehy-
drating diarrhoea are at higher risk of death in the 3-month
period after the onset of diarrhoea [4]. More recently, glo-
bal data suggest that multiple bacterial and parasitic diar-
rhoeal pathogens are significantly associated with death,
particularly in sub-Saharan Africa [1]. In low -resource set-
tings, the high burden of bacterial causes of diarrhoea [1, 3,
5] has led to suggestions that antibiotics be used more
widely, even in the absence of dysentery, as most children
with these infections do not have bloody stools [6, 7].
Despite WHO recommendations for the management
of diarrhoea which suggest that only children with
bloody diarrhoea receive antibiotics, over 40% of chil-
dren with non-bloody diarrhoea currently receive antibi-
otics as part of non-standard treatment in low-income
settings [22]. This overuse of antibiotics contributes to
the development and spread of antimicrobial resistance,
both at individual and population levels. While concerns
have been raised about expanding the use of empiric
antibiotic treatment for diarrhoea, targeting such treat-
ment to a specific sub-group of vulnerable children at
high risk of death may potentially lower antimicrobial
resistance if prescribers perceive that specific sub-groups
of children at the highest risk are being targeted with
antibiotic treatment. Prior studies in pneumonia have
documented reduced antibiotic use when guidelines
were updated to clarify which risk groups should be
treated [23]. The ABCD trial will determine if providing
azithromycin to children with acute diarrhoea who are
at risk reduces mortality and/or diarrhoea-related mor-
bidity, including linear growth faltering. These data will
inform the global debate regarding the potential role of
antibiotics in reducing child mortality.
If the ABCD trial demonstrates benefit, this will pro-
vide evidence to support a reconsideration of the present
WHO guidelines for the management of diarrhoea in a
clearly identified high-risk population. Conversely, if
there is no evidence of benefit, a convincing case for
more rigorous control over the inappropriate use of anti-
biotics in diarrhoeal case management and further
strengthening of global efforts to expand coverage and
improve coverage of the current Integrated Management
of Childhood Illness guidelines can be made.
Trial status
Recruitment to the ABCD trial began in December 2017
and is currently ongoing. It is expected to conclude in
March 2020. The current protocol is version 9.0 and is
dated 21 December 2018.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3829-y.
Additional file 1. SPIRIT Checklist for the ABCD trial.
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